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Abstract 
Background: Rapid commercial assays, including nucleic acid amplification tests and immunoassays for Clostridium. 
difficile toxins, have replaced the use of older assays. They are included in a two-step algorithm diagnosis, including 
first the detection of the glutamate dehydrogenase (GDH) as a screening method and second the detection of toxins 
as a confirmatory method. Although assays that detect the presence of free toxins in feces are known to lack sensitiv-
ity, they are preferable to confirm infection. We evaluated the accuracy of the chemiluminescence-based method 
detecting C. difficile GDH and free toxins A/B (DiaSorin algorithm) to an enzyme-immunoassay (EIA) for GDH with a 
molecular toxins test (Meridian algorithm), EIA-GDH and an EIA-toxins A/B algorithm (Alere algorithm) with and with-
out toxigenic culture for confirmation.
Findings: A total of 468 diarrhoeal and loose stool samples were included in the study. A positive result was defined 
by a positive GDH and a positive toxin test. Discordant samples were resolved using an enriched toxigenic culture 
considered as the reference method. After resolution, the DiaSorin algorithm showed a high sensitivity (86.7 %) com-
pared to that of the Alere algorithm with (60.0 %) and without (50.0 %) confirmation by culture and was as sensitive as 
the Meridian algorithm (90.0 %), while the specificities were similar: 99.1, 99.5, 99.5 and 98.9 %, respectively.
Conclusions: The DiaSorin algorithm was as sensitive as an algorithm including nucleic acid amplification test for 
toxins. Chemiluminescence toxin-enhanced signal assay compensates the lack of sensitivity usually observed for EIA 
tests for toxins.
Keywords: Clostridium difficile, Algorithm, Chemiluminescence, Diagnosis, Toxins, DiaSorin
© 2015 Goret et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Clostridium difficile is a major cause of healthcare-asso-
ciated diarrhoea. Many different approaches are avail-
able for the laboratory diagnosis of C. difficile infection 
(CDI). American [1] and European [2] guidelines rec-
ommend testing patients with a two-step algorithm 
including the detection of glutamate dehydrogenase 
(GDH) as a screening method followed, in case of posi-
tive result, by the detection of free toxins or their genes 
as a confirmation method. The DiaSorin Liaison® C. dif-
ficile GDH and toxins A and B (DiaSorin, Saluggia, Italy) 
is a sandwich chemiluminescent immunoassay (CLIA) 
performed on a stool extract. Luminescent assays for C. 
difficile diagnosis have not been previously reported in 
the literature. This method may be more reliable than 
enzyme immunoassays (EIA), which are known to lack 
sensitivity for free toxin detection. The objective of the 
study was to evaluate the performances of the newly 
available chemiluminescence-based DiaSorin algorithm 
for the detection of GDH and free toxins A and B using 
the Liaison apparatus in a routine laboratory.
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The DiaSorin algorithm was compared to three other 
algorithms: (1) a widely used EIA algorithm including, 
the C. Diff Quik Chek GDH® followed by detection of 
free toxins A and B, TOX A/B Quik Chek® test (Alere, 
Waltham, MA, USA), (2) the same EIA-based algorithm 
with toxigenic culture as a third step in case of negative 
toxin results; for this purpose, the stools were directly 
inoculated on a cycloserine-cefoxitin-amphotericin agar 
(bioMérieux, Marcy l’Etoile, France) incubated at 37  °C 
for 3  days in an anaerobic atmosphere and the isolates 
were then tested for toxins A and B using the TOX A/B 
Quik Chek® (Alere), and (3) a very sensitive algorithm 
[3–8] using the EIA ImmunoCard® C. difficile GDH for 
screening followed by a loop-mediated isothermal ampli-
fication assay for tcdA toxin gene detection (illumigene® 
Meridian, Cincinnati, OH, USA). The manufacturer’s rec-
ommendations were followed. All algorithms included 
a preliminary screening step for the detection of GDH 
and then, if positive, the stool samples were tested for 
toxins or toxin genes. The specimens that tested positive 
for the toxins were considered positive. The specimens 
that tested negative for GDH or for toxins were consid-
ered negative. In our study, the aggregate criteria for a 
true positive or a true negative result were a positive or 
negative result for the four algorithms, respectively. If 
an algorithm result was different from the three others, 
the sample was considered discordant. The discordant 
samples were resolved using enriched toxigenic culture 
(ETC) considered as a reference method and performed 
at the French National Reference Laboratory for C. diffi-
cile (Paris, France): stool samples were inoculated in pre-
reduced taurocholate-cycloserine-cefoxitin BHI broth 
incubated for 5  days at 37  °C under anaerobic condi-
tions; the broth was then plated onto laboratory standard 
selective plates containing taurocholate, cycloserine and 
cefoxitin. Toxinogenicity of the strains was demonstrated 
using an in-house polymerase chain reaction (PCR) tar-
geting tcdA and tcdB genes. After ETC, a stool sample 
was considered positive for toxigenic C. difficile if the 
toxin genes were detected.
Between June and September 2013, C. difficile 
testing was prospectively performed with the four 
different algorithms at the Bacteriology Laboratory of 
the Bordeaux University Hospital (Bordeaux, France) 
on diarrhoeal stools either upon a physician’s request 
or systematically inpatients with diarrhea after day 3 of 
hospitalization. As recommended in the literature [9] 
and manufacturers’ instructions, the followings sam-
ples were excluded: formed stools, bloody stools, stools 
submitted from a patient with a positive C. difficile test 
result in the preceding 7 days, stool samples which were 
received in the laboratory more than 48  h after emis-
sion, and samples from patients less than 2 years of age. 
A total of 468 stool samples were included in the study. 
Before resolution, the overall algorithm concordance was 
94.7 % (443/468) with 2.8 % true positive results (13/468), 
91.9 % true negative results (430/468), and 5.3 % (25/468) 
discordant results. The 25 discordant samples were sub-
jected to ETC (Table 1). Among the discordant samples, 
the DiaSorin algorithm showed 13 true positive, 4 true 
negative, 4 false positive and 4 false negative results after 
resolution. The sensitivity, specificity, positive and nega-
tive predictive values of the DiaSorin Liaison were 86.7, 
99.1, 86.7 and 98.1  % (Table  1), respectively. There was 
no significant difference for sensitivity and specificity 
between the DiaSorin and Meridian algorithm (90.0  %) 
using a molecular test (McNemar’s test, p = 0.72). More-
over, the DiaSorin algorithm exhibited a significantly 
higher sensitivity compared to that of Alere with toxi-
genic culture confirmation (60.0  %) and without confir-
mation (50.0  %). There was no significant difference in 
GDH results between the screening assays (CLIA and 
EIA): the overall concordance for GDH tests was 95.7 % 
with 15 % of positive results.
Since the algorithms were based on an initial GDH 
screening with no significantly different results observed, 
their performance was related to the part of the test 
confirming the toxins. As expected, the novel DiaSorin 
chemiluminescent algorithm has a high sensitivity indi-
cating that this sandwich ELISA-like test with enhanced 
signaling indeed compensates for the lack of sensitivity 
usually observed with EIA-based assays. Surprisingly, 
the overall performance of the DiaSorin algorithm was 
as high as the Meridian algorithm, already known to be 
Table 1 Clostridium difficile diagnostic test performances using enriched toxigenic culture as the reference standard
CLIA chemiluminescence, GDH glutamate dehydrogenase, EIA enzyme immunoassay, NAAT nucleic acid amplification test, CI 95 % confidence interval
(%) Sensitivity  
(95% CI)
(%) Specificity  
(95% CI)
Positive predictive  
value (%) (95% CI)
Negative predictive 
value (%) (95% CI)
DiaSorin algorithm = CLIA GDH + CLIA toxins A/B 86.7 (68.4–95.6) 99.1 (97.7–99.8) 86.7 (68.3–95.6) 98.1 (97.5–99.7)
Meridian algorithm = EIA GDH + NAAT for toxin gene 90.0 (72.3–97.8) 98.9 (97.4–99.5) 84.4 (66.5–94.1) 99.3 (97.8–99.8)
2-Step Alere algorithm = EIA GDH + EIA toxins A/B 50.0 (31.7–68.3) 99.5 (98.1–99.9) 88.2 (62.2–97.9) 96.7 (94.5–98.1)
3-Step Alere algorithm = EIA GDH + EIA toxins  
A/B + toxigenic culture
60.0 (40.7–76.7) 99.5 (98.1–99.9) 90.0 (66.8–98.2) 97.3 (95.2–98.5)
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very accurate. Combining this two-step algorithm with a 
confirmation test was not required. Moreover, tests that 
detect the presence of free C. difficile toxins in feces are 
significantly associated with clinical outcomes [10]. A 
retrospective chart review was performed for all the posi-
tive results of the DiaSorin algorithm. There was a good 
correlation with clinical pictures (Table 2).
The limitation of the study was the small number of 
positive cases rendering the estimation of sensitivity with a 
large confidence interval. Given the low incidence of CDI in 
this population, a larger number of specimens should have 
been evaluated. Choosing the right diagnostic approach 
is a matter of test accuracy, turnaround time, and cost for 
routine use in a clinical laboratory. In conclusion there is 
a good performance of the DiaSorin assay in comparison 
to the three other approaches. This method is sufficient for 
the diagnosis of CDI and there is no need for a confirma-
tion test because the sensitivity of the test is as high as the 
molecular method. This algorithm could replace the others.
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Table 2 Turnaround time and reagent costs to detect Clostridium difficile infection in the laboratory
The cost of each algorithm was evaluated in comparison to the DiaSorin algorithm whose the global costs represent 100 %
a The DiaSorin LIAISON® apparatus is configured in order to automatically perform the toxin assay in case of a positive GDH result (reflex testing). These two assays 









Apparatus Individual or 
series test
Algorithm cost ratio 
relative to DiaSorin 
algorithm (%)
DiaSorin GDH Yes 15 45 Liaison random access Both 100
Toxins A and B Yesa 0a 45 Liaison random access Both
Meridian ImmunoCard® GDH No 5 30 No Individual 90
illumigene® No 15 45 illumipro® Individual
Alere C. DIFF Quik Chek GDH® No 5 30 No Individual 50
TOX A/B Quik Chek® No 5 30 No Individual
